Seminars in Oncology
Volume 32, Issue 2 , Pages 156-164, April 2005

Palliative radiation therapy

  • Andre Konski

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to Andre Konski, MD, Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111
  • ,
  • Steven Feigenberg

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • ,
  • Edward Chow

      Affiliations

    • Department of Radiation Oncology, Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada

Radiation is an effective modality to aid in symptom management of patients with metastatic disease. The type and duration of treatment depends on the Karnofsky performance status (KPS) of the patient and type and status of the cancer. Abbreviated treatment regimens may be favored in this patient population. They provide quick palliation without the patient and family spending significant time traveling back and forth to the treatment center. Hypofractionated regimens have been found effective in relieving pain from metastatic bone disease, relieving obstruction from locally advanced lung cancer, bleeding from gynecologic cancers, and hematuria from advanced bladder cancer. More aggressive regimens such as whole-brain radiation therapy (WBRT) and stereotactic radiosurgery may be appropriate for select patients with a good KPS. Radiation has also been found to be effective in palliating recurrent cancer that has already received definitive radiation.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00570-6

doi:10.1053/j.seminoncol.2004.11.013

Seminars in Oncology
Volume 32, Issue 2 , Pages 156-164, April 2005